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1 Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised 
2 trial of palate surgery at 6 months versus 12 months of age 
3 Authors:William Shaw1a, Gunvor Semb1a, Anette Lohmander2, Christina Persson3, Elisabeth 
4 Willadsen4, Jill Clayton-Smith1c, Inge Kiemle Trindade5, Kevin J Munro1b, Carrol Gamble6, Nicola 
5 L Harman6, Elizabeth J Conroy6, Dieter Weichart1a, and Paula Williamson6
6 Correspondence to Professor William Shaw, The University of Manchester, Division of Dentistry, 
7 Coupland 3 Building, Manchester M13 9PL email: bill.shaw@manchester.ac.uk
8
9 ABSTRACT 
10 Introduction: Cleft palate is amongst the most common birth abnormalities. The success of primary 
11 surgery in the early months of life is crucial for successful feeding, speech, hearing, dental 
12 development and facial growth. Over recent decades, age at palatal surgery in infancy has reduced. 
13 This has led to palatal closure in one-stage procedures being carried out around the age of 12 months, 
14 but in some cases as early as 6 months. The primary objective of the TOPS trial is to determine 
15 whether surgery for cleft palate performed at 6 or 12 months of age is most beneficial for speech 
16 outcomes. 
17 Methods and analysis: Infants with a diagnosis of non-syndromic isolated cleft palate will be 
18 randomised to receive standardised primary surgery (Sommerlad technique) for closure of the cleft 
19 at either 6 months or 12 months, corrected for gestational age.  The primary outcome will be perceived 
20 insufficient velopharyngeal function at 5 years of age. Secondary outcomes measured across 12 
21 months, 3 and 5 years will include growth, safety of the procedure, dentofacial development, speech, 
22 hearing level and middle ear function. Video and audio recordings of speech will be collected in a 
23 standardised age-appropriate manner and analysed independently by multiple speech and language 
24 therapists (SLTs). The trial aims to recruit and follow up 300 participants per arm. Data will be 
25 analysed according to the intention to treat principle using a 5% significance level. All analyses will 
26 be pre-specified within a full and detailed statistical analysis plan. 
27 Ethics and dissemination: Ethical approval has been sought in each participating country according 
28 to country specific procedures. Trial results will be presented at conferences, published in peer-
29 reviewed journals and disseminated through relevant patient support groups.
30 Protocol version 5.0 22nd August 2018
31 Registration details: ClinicalTrials.gov Identifier NCT00993551.
32 Funding: US National Institutes of Health (funder reference: 5U01DE018664/1U01DE018837)
33
34 Keywords: unilateral cleft palate, randomised clinical trial, TOPS, palatal surgery,  
35 velopharyngeal function, syllable inventory, Sommerlad technique
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2
36 Strengths and limitations of the study
37  
38  International trial covering speech development in children across Scandinavia, the UK, 
39 and Brazil
40   Surgical repair was calibrated across surgeons who were all trained in the Sommerlad 
41 technique.
42  Longitudinal speech assessments at 12 months, 3 and 5 years will be independently 
43 analysed by multiple speech and language therapists whose ratings will be calibrated on 
44 practice recordings.
45  Standardised assessments of additional outcomes include postoperative complications, 
46 hearing levels, middle ear function and dentofacial development.
47  The study excludes co-existing conditions such as syndromic cleft palate or severe 
48 developmental delays that are known to adversely affect speech development or its 
49 assessment
50 INTRODUCTION
51 Clefts of the lip and/or palate, occurring with an incidence of about 1 per 600 births, are among the 
52 most common birth anomalies. This trial will focus on isolated clefts of the palate, which occur with 
53 a global incidence of 4.5 per 10,000 births (1). Depending on geographic location, the prevalence of 
54 isolated clefts of the palate ranges from 1.8 to 14.6 per 10,000 (1).
55 The timing of palatal surgery has been a controversial issue since the 1930s (2). Traditionally, 
56 rationale for delaying hard palate surgery was partly based on the belief that postponing the trauma 
57 of palatal closure may reduce maxillary growth disturbance. However, there is little evidence that 
58 facial skeletal growth in individuals with isolated cleft palate is substantially affected by different 
59 surgical protocols, though maxillary arch form, especially transversely, may be affected (3-6). 
60 Over recent decades, the age at which palatal surgery is carried out has reduced. This has led to one-
61 stage palatal closure within 12 months of age at cleft units in Europe and the USA. Protagonists of 
62 early closure of the palatal cleft have proposed that since speech is a learned behaviour, the sooner 
63 an intact anatomy is created, the better (7-10). As yet however, there is no evidence that early surgery 
64 would lead to better speech development. 
65 Rationale
66 The widespread uncertainty surrounding the timing of palatal closure was reflected in the diversity 
67 of protocols currently employed by  the Scandcleft Research Group,  a partnership of Scandinavian 
68 and UK cleft lip and palate centres (11-22). The Scandcleft Research Group, identified this 
69 uncertainty as a priority research question for a future trial. Its aim was to determine whether, in 
70 infants with cleft palate, repair at either age 6 or at 12 months (corrected for gestational age) would 
71 achieve better speech outcomes. The design of the trial was supported by a planning grant from the 
72 National Institute of Dental and Craniofacial Research (NIDCR), a substream of the US National 
73 Institute of Health, who subsequently funded the proposed trial.
74 Objectives
75 The aim of this project is to determine whether, in infants with isolated cleft palate, it is better to 
76 perform primary surgery at age 6 or 12 months (corrected for gestational age). Gestational age will 
77 be assessed based upon the date of the last menstrual period and the infant’s date of birth (full term 
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78 defined as day 1 of the 40th week of pregnancy), thus taking account of prematurity. This research 
79 will investigate the effect of the timing of surgery by assessing and comparing speech development 
80 outcomes measured across 12 months, 3 years and 5 years. In addition, secondary outcomes include 
81 growth, perioperative complications, dentofacial development, hearing level and middle ear function.
82 METHODS AND ANALYSIS
83 Design
84 Timing Of Primary Surgery for cleft palate (TOPS) is an international, multi-site trial using a parallel 
85 arm design aiming to detect whether surgery at 6 months is superior to surgery at 12 months. Infants 
86 will be randomised to receive primary surgery for cleft palate using a standardised technique (the 
87 Sommerlad technique (23)) at either age 6 or age 12 months (corrected for gestational age). The study 
88 design of TOPS trial is illustrated in Figure 1.
89 Setting
90 The trial will be conducted by the cleft palate teams based in centres across the UK, Scandinavia and 
91 Brazil. Criteria for selection of sites is based primarily on ability to enrol a high volume of patients 
92 into the trial. A list of the TOPS trial sites is provided in Table 1. The cleft team at each centre 
93 generally includes cleft surgeon(s), nursing staff, cleft speech and language therapist(s), clinical 
94 geneticist(s)/paediatrician(s), audiologist(s), orthodontist(s) and psychologist(s)/social worker(s) 
95 Table 1: TOPS trial clinical sites
Country Sites
Brazil University of São Paulo (HRAC Bauru)
Denmark Copenhagen Cleft Palate Centre / Århus Speech and Hearing Institute
Oslo University HospitalNorway Helse Bergen HF
Malmö University Hospital
Göteborg University
Karolinska University Hospital (Stockholm)
University of Linköping
Umeå University
Sweden
Uppsala University
Royal Manchester Children’s Hospital
Alder Hey Children’s NHS Foundation Trust
Royal Belfast Hospital for Sick Children
Birmingham Children’s Hospital
Royal Victoria Infirmary,  Newcastle
University Hospitals Bristol NHS Foundation Trust
Morriston Hospital, Abertawe Bro Morgannwg University Hospital 
Board,  Swansea
Leeds General Infirmary 
Royal Hospital for Sick Children, Glasgow
Royal Hospital for Sick Children, Edinburgh
Salisbury NHS Foundation Trust
United Kingdom
The Children’s Hospital , John Radcliffe Hospital, Oxford
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96 Eligibility criteria
97 All infants referred to the participating specialised cleft lip and palate centres are eligible to enter the 
98 trial if they meet the following inclusion and none of the exclusion criteria:  
99 a. isolated cleft palate;
100 b. medically fit for surgery at 6 months, corrected for gestational age;
101 c. Written informed proxy consent;
102 d. One parent/carer must be a native language speaker of the majority language in the country 
103 of residence.
104 Infants with any of the following will be excluded from the study:
105 a. Consent not obtained;
106 b. Infants with severe developmental delay (as measured on DENVER II)or syndromic cleft 
107 palate (except Van der Woude syndrome, which can be included if hearing is not affected) 
108 will be excluded;
109 c. Congenital sensorineural hearing loss or structural middle ear anomalies;
110 d. Sommerlad technique could not be performed due to variation in the anatomical presentation;
111 e. Infants presenting with submucous cleft palate (defined by the classical triad of signs, bifid 
112 uvula, bony defect of the hard palate, muscular diastasis, as described by Jensen et al. (24))
113 f. Where the language spoken at home by at least one parent is not the majority language in the 
114 country of residence.
115 Since not all syndromic disorders will present prior to recruitment, all participants will undergo 
116 genetic testing to exclude chromosome abnormalities at the time of surgery. If a chromosome 
117 abnormality or another genetic syndrome is identified later in the study the data for these participants 
118 will be analysed separately. The same will apply if the participant fails the DENVER II 
119 developmental test at 3 year follow up. 
120 Consent
121 Informed consent will be sought from the infant’s parent/guardian by a member of the local trial 
122 team, and families who decline to participate will receive surgery in line with the hospital’s current 
123 practice together with the same level of care and support as families participating in the trial. Consent 
124 forms used in the TOPS trial in the UK are shown in Supplementar  Materials Nos. 1, 2 and 3; these 
125 forms were adapted and translated for use in the other participating countries while maintaining key 
126 content. The final consent forms in Brazilian-Portuguese, Danish, Norwegian and Swedish were 
127 translated to English to check for accuracy and completeness. Participants can withdraw from the 
128 trial at any time without giving an explanation, and their child’s care will not be affected.
129 To reduce potential burden to families, where possible, trial information will be collected at visits 
130 scheduled in line with routine visits made to the site as part of the infant’s ongoing care. 
131 Randomisation
132 Infants meeting the eligibility criteria will be randomised to 6 or 12 month surgery, corrected for 
133 gestational age, in a ratio 1:1 using a minimisation routine incorporating a random element to reduce 
134 predictability. Allocations will be delivered via a password protected web-based system.  
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135 Every effort will be made to arrange surgery within one of week of the target date. However, surgery 
136 may take place up to two weeks before or four weeks after the target date. The estimated timing of 
137 surgery and the allowed time window for the surgery will be calculated by the online randomisation 
138 system and provided to the trial site at the time of randomisation. 
139 Interventions
140 The Sommerlad surgical technique (23)] will be used in all participants at 6 months or 12 months 
141 corrected for gestational as determined by randomisation. This technique will be standardised across 
142 all surgeons, including those who already use the technique, by receiving direct instruction from Mr 
143 Brian Sommerlad in the operating theatre. Written descriptions and a video of the surgical procedure 
144 will also be provided. 
145 Blinding
146 The nature of the interventions prevents this trial from being blind to participants or their carers. 
147 However, speech and audiometry outcome assessments, at age 3 and 5 years, will be conducted and 
148 rated blind to the randomly allocated group.
149 Outcome Measures
150 The primary endpoint for the TOPS trial is defined as a dichotomous outcome of whether the child 
151 has been perceived by the SLTs to have insufficient velopharyngeal function at age 5 years or not. 
152 Adequate velopharyngeal function is a prerequisite for normal speech production.  In children born 
153 with cleft palate, speech outcomes are often reported for velopharyngeal function and articulation. 
154 In the presence of insufficient velopharyngeal function, speech will inevitably be affected by 
155 symptoms such as hypernasality and nasal air emission to different degrees. In children with isolated 
156 cleft palate, articulation disorders occur less frequently than in children with complete cleft lip and 
157 palate. Insufficient  perceived velopharyngeal function was therefore chosen to be the primary 
158 outcome and articulation outcomes as secondary outcomes.  Velopharyngeal insufficiency is 
159 measured by velopharyngeal (VPC) sum, which is an overall score on the scale 1-6 (25). Scores ≥4 
160 on this scale will be considered insufficient. 
161 The secondary endpoints are summarised in Box 1and Table 2 (Schedule of Assessments).
162
163
Page 6 of 39
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
TOPS Trial Protocol paper_V12.0 16 05 2019.docx
6
164 Box 1: Secondary Endpoints 
1. Velopharyngeal function at age 5 years; 
a. Velopharyngeal composite score summary (VPC sum) 
b. Insufficient velopharyngeal function (VPC rate) 
2. Velopharyngeal function at age 3 years;
a. Insufficient velopharyngeal function (VPC rate) 
b. Velopharyngeal insufficiency symptoms 
3. Canonical babbling at age 12 months:
a. Canonical babbling present 
b. Canonical babbling ratio 
c. Consonant inventory 
4. Articulation at age 3 years:
a. Percent consonants correct (PCC) 
b. Percent correct placement (PCP) 
c. Percent correct manner (PCM) 
d. Non-oral consonant errors 
e. Oral consonant errors 
5. Articulation at age 5 years:
a. Percent consonants correct (PCC)
b. Percent correct placement (PCP)
c. Percent correct manner (PCM)
d. Non-oral consonant errors 
e.  Oral consonant errors 
6. Postoperative/long term complications: 
a. Dehiscence
b. Infection
c. Evidence of fistula
7. Hearing level:  
a. At 12 months
i. Abnormal Transient Otoacoustic Emission (TEOAE)
ii. Abnormal Soundfield audiometry
b. At 3 and 5 years
i. Abnormal Puretone audiometry in at least one ear
ii. Abnormal Puretone audiometry in both ears
iii. Severity of better ear (normal, mild, moderate, severe, profound) 
8. Middle ear function
a. Flat line Tympanogram in at least one ear (12 months, 3 years, 5 years) 
b. Flat line Tympanogram in both ears (12 months, 3 years, 5 years)
9. Dentofacial development at age 5 years:
a. Soft tissue ANB (the angle between soft tissue nasion, A point, and B point on a profile photograph)
b. Maxillary arch constriction score (using modified Huddart/Bodenham scoring system)
10. Growth at 12 months: 
a. Nude weight
b. Crown to heel length
c. Occipitofrontal circumference
165
166 Speech outcome assessments
167 To ensure quality of speech data, all sites will receive identical high quality recording equipment 
168 (video recorder JVC-GY-HM100 series, audio recorder H4n/H5 Handy recorder, and microphone 
169 Rode NT4/NT5) to be used at each follow-up recording according to a detailed standard operating 
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170 procedure. Before data collection starts at each follow up age, all SLTs will participate in a three-day 
171 calibration meeting. Afterwards, a series of video-audio practice recordings will be completed and 
172 quality checked. When sufficient recording quality has been reached, the site receives approval that 
173 they can start the trial recordings. To train the SLTs who are going to perform blinded speech 
174 assessments, a specific procedure has been developed. This includes theoretical lectures on 
175 development of speech and language in children with cleft palate and methodological considerations 
176 on assessment/rating, and listener training with discussions and personal feedback. Before the 
177 assessments start, all SLTs need to pass a test with a specified level of intra- and inter-rater reliability. 
178 They also have to pass a hearing test.
179 At 12-months of age, assessments will be done cross-linguistically. At age 3 and 5, SLT rating will 
180 be confined to records of children sharing the SLT’s native language.  
181 Vocalisations of 12-month old children will be assessed with adjusted real time listening, as described 
182 by Ramsdell et al (26). The SLTs will listen to a 45 minutes video recording, of a play session between 
183 the child and carer, divided in two parts (22 minutes each). The SLT will register every syllable a 
184 child produces as canonical or not, in real time, using a software, TimeStamper, specifically 
185 developed for this study  (27). At the end of each recording, the SLT indicates if the child babbled 
186 canonically or not, and lists the syllables the child produced with control. In this way, the variables 
187 canonical babbling present, canonical babbling ratio, and consonant inventory are obtained. 
188 The methodology for the 5-year assessment of articulation and velopharyngeal function cross-
189 linguistically was developed within the Scandcleft study (12, 18, 22) and will be extended to include 
190 Brazilian Portuguese. At the 5-year assessment, 36 target consonants from the TOPS single word test 
191 will be transcribed phonetically for assessment of articulation and VPI-symptoms. Target words 
192 include similar target sounds in the same position and with similar phonetic context across languages. 
193 Further, repetition of sentences and continuous speech are collected, as well as nasalance scores 
194 (NasometerTM), and parent-reported intelligibility estimates of how well their children’s speech is 
195 understood by different listeners (Intelligibility in context scale (28)). The 3-year assessment will be 
196 based on 30 of the 36 words used in the 5-year assessment, and target consonants will be transcribed 
197 phonetically for assessment of articulation. Error types will be classified automatically by a 
198 predefined script that will also allow calculation of PCC, PCP, and PCM. The VPC-rate will be rated 
199 by SLTs from continuous speech both at age 3 and 5 years
200
201 Table 
202 2: 
203 Schedule of Assessments
Outcome 
Measures
Assessment  Schedule 
(age is corrected for gestational age)
Post-surgery 12 
months
3 
years
5 
years
  Assessments
48 hours 30 days
Dehiscence      
Infection      
Surgical 
Complications
Evidence of Fistula     
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Nude Weight      
Crown to heel length      
Growth
Occipitofrontal 
Circumference
     
Canonical Babbling 
presente
     
Canonical Babbling ratioe      
Canonical 
Babbling
Consonant Inventorye      
Velopharyngeal composite 
score summary (VPC-
sum)
    a,b
Insufficient 
Velopharyngeal function 
(VPC rate)
   c d
Velopharyngeal 
Function
Velopharyngeal 
insufficiency Symptoms
   a  
Percent Consonant Correct 
(PCC)a
    
Percent Correct Placement 
(PCP)a
    
Percent Correct Manner 
(PCM)a
    
Non-oral consonant errorsa     
Articulation
Oral Consonant errorsa     
Abnormal Transient 
Otoacoustic Emission 
(TEOAE)
     
Abnormal Soundfield 
Audiometry
     
Abnormal Pure Tone 
Audiometry in at least one 
ear*
    
Abnormal Pure tone 
Audiometry in both ears*
    
Severity of better ear*     
Hearing Level
Soundfield Audiometry*     
Flat Line Tympanogram in 
at least one ear
    Middle Ear 
Function
Flat Line Tympanogram in 
both ear
    
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204
205
206
207
208
209
210
211
212
213
214 *: if puretone audiometry could not be performed then Soundfield audiometry will be performed
215 **: the angle between soft tissue nasion A point and B pint on a profile photograph 
216 ***: maxillary arch constriction score is determined using modified Huddart/Bodenham scoring system
217 ****: DENVER II developmental Assessment is carried out at the time of surgery
218 *****: Local site questionnaire sent to local speech and language therapists outside TOPS research team to 
219 collect data on direct and indirect therapy given to the child  in the intervals between assessment visits
220 Sources of speech assessments; a: TOPS picture naming test, b: nine word string, c: spontaneous 
221 speech, d: spontaneous speech (retelling of bus story) and e: video of play interaction.
222
223 Patient and Public Involvment
224 Parents of children with cleft palate were approached by their orthodontist / surgeons prior to 
225 enrolment. Patients and their parents were not initially involved in the design of the study.  However, 
226 a representative from the Cleft Lip & Palate Association (the charity for Cleft Lip & Palate in the 
227 UK) is a member of the Trial Steering Committee. Therefore, providing ongoing insight from a parent 
228 perspective with regards to the execution of this study and the dissemination of results.
229 Data collection and management
230 Trial data will be recorded on Case Report Forms (CRFs) and identifiable only by randomisation 
231 number. The data from completed CRFs will be entered onto the trial specific MACRO database by 
232 the Data Manager or appropriately trained personnel at the Data Coordinating Centre.
Soft Tissue ANB**     Dentofacial 
Development Maxillary arch 
Constriction score***
    
DENVER II 
Developmental 
Assessment****
   
Intelligibility in Context 
Scale Questionnaire for 
parents (ICS)
    
Others
Local site 
questionnaire*****
    
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233 Video and audio recording 
234 Once recorded, video and audio recordings will be saved onto encrypted USB drives. They will be 
235 posted to the Data Coordinating Centre where, upon receipt, they will be logged and stored onto the 
236 trial specific secure server. This server will be backed up once a day to ensure data is not lost once 
237 received. Recordings are quality checked by the Core Speech Group and/or the Trial Administrative 
238 Centre. A satisfactory recording is one that passes pre-specified quality checks on lighting, length 
239 and sound. Quality checks will be performed regularly and feedback to site will be provided on their 
240 suitability for assessment. 
241 Maxillary arch impressions
242 Maxillary arch impressions will be obtained at the time of surgery to provide a mould for plaster 
243 casts, which are sent to the TOPS Administrative Centre at the University of Manchester.
244 In addition, impressions of the maxillary and mandibular dental arches will be obtained at the 5 year 
245 follow-up appointment. Impressions are taken by a designated member of staff (usually the 
246 orthodontist) using appropriate impression material. The occlusion will be registered with a wax 
247 wafer in the position of maximal intercuspation. The study models made from the impressions will 
248 be stored at the TOPS Administrative Centre.
249
250 Photographs
251 Intra-oral photographs will be  taken at the time of surgery, and frontal and lateral photographs will 
252 be obtained at the 5-year visit. The photographs will be saved onto encrypted USBs, upon receipt by 
253 the Data Coordinating Centre they will be logged and stored onto trial specific secure hard drives. 
254 Statistical analysis and sample size considerations
255 Proposed sample size
256 300 patients per arm will allow a reduction in insufficient velopharyngeal function at 5 years from 
257 40% to 29% to be detected with 81% power using a chi-square test (2 sided significance test at 0.05 
258 level). The estimate of 40% was obtained from a pilot trial in 50 five year of patients, collected during 
259 the planning period for this grant application (12). To allow an approximate drop out of 10%, 648 
260 participants will be recruited. However to consider the potential impact of variability around the value 
261 of 40%, 300 patients per group would provide 80% power to detect a reduction from 30% to 20% 
262 and 76% power to detect a reduction from 20% to 12%.
263
264 The trial enrolment, allocation, follow up and analysis will be reported using the “Consolidated 
265 Standard of Reporting Trials‟ (“CONSORT”) (29) and the International Conference on 
266 Harmonisation E9 guidelines (30).   A full and detailed statistical analysis plan (31) will be developed 
267 prior to the final analysis of the trial. The main features of the statistical analysis plan are included 
268 here.
269 The primary analysis will be by intention-to-treat principle, as far as is practically possible using a 
270 5% significance level throughout. Rather than adjust for multiplicity of secondary outcomes, relevant 
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271 results from other studies already reported in the literature will be taken into account in the 
272 interpretation. The approach to formal analyses will be dependent on outcome type as follows:
273  Dichotomous outcome will be compared between the two groups using a chi-squared test and 
274 the effect estimate will be reported in terms of the relative risk and 95% confidence interval.
275  Short ordinal outcomes will be compared using a chi-squared test for trend.
276  Continuous and long ordinal outcomes will be compared between the two groups using a two 
277 group t-test. The difference in means will be presented with a 95% confidence interval.
278 Baseline and operative characteristics and safety data will be presented using descriptive statistics 
279 only.
280 If the percentage of major protocol deviations exceeds 10% and the trial management group consider 
281 this analysis appropriate, a per protocol analysis in which pre-specified major protocol deviations 
282 indicate exclusion of a participant from the analysis set  will be conducted. 
283 Trial oversight and monitoring
284 The Trial Management Group (TMG), Trial Steering Committee (TSC) and Data Safety and 
285 Monitoring Board (DSMB) will provide ongoing oversight and will monitor accruing trial data. The 
286 roles, responsibilities and composition of each of these committees are provided in Supplementary 
287 Material No. 4. A risk assessment has been conducted and used to inform a trial specific monitoring 
288 plan agreed by the independent oversight committees.
289 Trial status and timeline
290 The overall programme commenced 13/07/2010. Applications for ethics approval were submitted 
291 10/11/2009. Recruitment to the trial commenced 13/07/2010. Participants will be followed up until 
292 30th July 2020. 
293 This trial completed recruitment on 21st July 2015 and the last patient is due to attend their last visit 
294 until 30th of July 2020.
295
296 ETHICS
297 The trial will abide by the principles of the World Medical Association Declaration of Helsinki (1964) 
298 and the Tokyo (1975), Venice (1983), Hong Kong (1989) and South Africa (1996), the Office of 
299 Human Research Protections (OHRP) Common Rule, 45 CFR 46 and General Data Protection 
300 Regulations (GDPR), accompanied by UK Data Protection Act (2018).
301 Ethical approval has been sought in each participating country according to country specific 
302 procedures. The protocol has gained favourable opinion from the Multicentre Research Ethics 
303 Committee in the UK and from relevant ethics committees for each participating centre.  TOPS 
304 Protocol Version 1.1 (of 02 November 2009) was approved by UK ethics on 8 January 2010, the 
305 Protocol Version 4.0 (of 26 August 2015) was approved by UK ethics on 01 October 2015 and the 
306 Protocol Version 5.0 (of 22 August 2018) was approved by UK ethics on 18 November 2018. A 
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307 summary of substantial protocol amendments and relevant ethics committees is provided in 
308 Supplementary Material No. 5.
309
310 DISSEMINATION
311 Following completion of the study, the Principal Investigator is expected to publish the results of this 
312 research in a peer-reviewed scientific journal. According to the National Institute of Health (NIH) 
313 Public Access Policy, all journal articles arising from this NIH funded trial will be submitted to the 
314 digital archive PubMed Central. Trial investigators have the right and responsibility to communicate 
315 their findings to the scientific community and to the public. Findings of the trial will also be presented 
316 at National and International meetings of relevant professional bodies and research groups. Reports 
317 will also be posted on the WHO website (www.who.org) craniofacial section. Access to clinical data 
318 sets within speech, genetic, surgical and other fields will be available to others following the 
319 acceptance for publication of the main findings from the final dataset. Requests to access data will 
320 be subject to participant confidentiality concerns, and to contemporary NIH guidance on data-sharing 
321 plans.
322
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Figure 1: Flow diagram of the TOPS Trial study design
*Infants having surgery at 12 months will have their 12 month assessment prior to surgery 
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TOPS PISC Pilot Study Version 4.0  20-April-2015 
4.  What will happen if I choose for my child to take part? 
If your child is aged 14 months or younger 
Your speech therapist will make an audio and video recording of a play situation between you and 
your child. The purpose of this recording is to analyse the babbling of your child as it is known to be 
of importance for the language development. 
If your child is aged 34 months or older 
At the visit the speech therapist will ask your child to say a number of words (between 30 and 36) 
that have been carefully selected to allow assessment of all aspects of your child’s speech. The 
speech therapist will make an audio and video recording of your child saying these words, and also a 
recording from spontaneous speech during a play session. 
If your child is aged 58 months or older, your child will be asked to repeat sentences and retell a 
story. We will also ask your child to speak into a special microphone connected to a computer.  This 
will assess how much nasal interference there is with your child's speech.  You will also be asked to 
complete a very short questionnaire about how understandable your child's speech is to different 
people. 
5.       What happens to the video recording?  
The audio/video recording of your child will be used as part of the training of your speech therapist. It 
will also be used to develop a training package for all of the speech and language therapists involved 
in the TOPS trial.   
 We are doing this so that all of the speech therapists in the TOPS trial follow the same method. We 
would also like to ask your permission to use this recording to help train speech therapists involved in 
future studies.  
6. What will I have to do if my child takes part? 
We would like you to keep the appointment made to see your child’s speech therapist, in some cases 
this will be a usual visit or you may be asked to come for an additional appointment.  
 Your visit will last around 40-60 minutes.  
7. Are there any possible disadvantages and risks or side-effects of taking part? 
The speech assessment made by the speech therapist is standard practice with no known risk to your 
child. The audio and video recording has no known risk to your child. 
8. What are the possible benefits of taking part? 
Taking part in this study is unlikely to provide any direct benefit to your child. However, your child’s 
recording will help to train speech and language therapists taking part in the TOPS trial which aims to 
find out if the timing of surgery for cleft palate repair influences a child’s speech. The methods we 
develop for assessing speech may also help improve how we do future research and how speech is 
assessed in clinical practice.  
9. What will happen if something goes wrong? 
In the event that something does go wrong due to negligence then you may have grounds for legal 
action for compensation against <Centre Name> but you may have to pay your legal costs. 
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TOPS PISC Pilot Study Version 4.0  20-April-2015 
If you have a concern about any aspect of the pilot study you should ask to speak to a member of the 
cleft team who will do their best to answer your questions (contact number below). 
The normal complaints mechanisms in place at <Centre Name> will still be available to you.  Details 
can be obtained from the hospital. 
10. What happens if I want to withdraw my child from the study? 
You may withdraw your child from the study at any time if you wish. If you withdraw your child from 
the study your child’s ongoing and future care will not be affected by your decision. If you choose to 
withdraw your child from the study you may also choose for audio/video recordings already made to 
be destroyed.  
11. Will my child taking part in the study be kept confidential? 
All information that is collected about you and your child during the course of the study will be kept 
strictly confidential, and any information that leaves <centre name> will have your child’s name and 
address removed.  
We would like to ask your permission to use the audio and video recording for the training of speech 
and language therapists involved in the TOPS trial and also in future studies about cleft palate. To do 
this, a copy will be sent to the Data Coordinating Centre in Liverpool who will store the audio and 
video recording securely and identified by a unique number only. We would also like to ask your 
permission for a copy of the consent form, which will have your and your child’s name on it, to be 
sent to the Data Coordinating Centre at the University of Liverpool. 
All legal requirements applying to research of this kind will be strictly adhered to. 
 
12. What will happen to the results of the study? 
The results of the sample speech recordings made in this study will be used to standardise the 
method of speech sample collection across the TOPS trial. The TOPS trial will assess the effects of the 
timing of primary surgery for cleft palate on speech development.   If you would like a copy of the 
final TOPS trial report you can indicate so on the consent form. 
 
13. Who is organising and funding the research? 
This study and the TOPS trial have been planned by an international collaboration of cleft specialists.  
The Administrative Centre for the projects is the University of Manchester, UK, and the Data 
Coordinating Centre for the projects is the University of Liverpool, UK.  The study is funded by the 
National Institute of Dental and Craniofacial Research in the USA.   
14. Who has reviewed the study? 
All research is looked at by an independent group of people called a research ethics committee to 
protect you and your child’s safety, rights, wellbeing, and dignity.  This study has been reviewed and 
given a favourable opinion by Yorkshire and the Humber – Leeds East Research Ethics Committee. 
 
Contact for further information 
If you would like more information about the study please contact: 
<Site Coordinator Name> 
<Site coordinator Contact Number> 
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Dear Parent,  
The TOPS trial that you and your child are taking part in will assess the timing of primary surgery in 
children with cleft palate.  We have made some changes since you agreed to be in the trial and would 
like to let you know about these and to check you are happy with them. There are two changes aimed 
at improving the data we collect about your child’s speech: 
1. We would like to send a questionnaire to other therapists outside of <centre name> who have 
provided speech therapy for your child. This questionnaire will ask how many and what type of 
speech therapy sessions your child has had.  
2. When you attend for your child’s age 5 speech follow up  we will ask you to complete a short 
questionnaire about how well your child is understood by others. The questionnaire has 7 
questions and takes about 5 minutes to complete.  
These changes have been looked at and approved by an independent group of people called a 
research ethics committee (The Yorkshire and the Humber– Leeds East Research Ethics Committee).  
 
Please tell us if you are happy with ach of these changes, or not, by completing the section 
below and returning this form in the addressed envelope provided. We have included a copy 
of the information for you to keep. 
 
If you would like more information about these changes before you make a decision please contact: 
<Site Coordinator Name>, <Site coordinator Contact Number> 
Randomisation 
Number                         
To be completed by the research team 
Date sent/given to 
parent   d  d   m  m   y  y 
Centre Name    Centre ID   
I agree to my local speech therapist being contacted about my 
child’s speech therapy sessions. 
Yes               No   
I am happy with the changes made to the 5 year follow up visit and 
understand I will be asked to complete a short, 5 minute, 
questionnaire when I attend.  
Yes               No   
Please Ɵck  and iniƟal in the spaces below 
  Tick ()  IniƟals 
Your name       
Your signature    Today’s Date   
       
Your child’s name    Your child’s date of birth   
       
       
Date received at 
site   d  d   m  m   y  y  Received by (Signature)   
When complete, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in 
the medical notes. A copy of the consent form only should be faxed to the  
Data Coordinating Centre on +44 (0) 151 282 4721 
Sent by (Signature)   
TOPS addiƟonal informaƟon and consent form 
V1.0  30‐March‐2015 
Important changes to the TOPS trial 
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Supplementary Material No. 4: TOPS Trial Committees 
1.1 Trial Management Group (TMG) 
 
The Trial Management Group (TMG) comprises members of the Administrative and Data 
Coordinating Centres and representatives of the core speech group and National Institute of 
Dental and Craniofacial Research. The Trial Management Group is responsible for the day-to-
day running and management of the trial. The Trial Management Group will meet monthly in 
the first instance and a minimum of four times a year, attendance at Trial Management Group 
meetings will be by teleconference.  Other meetings will be held by teleconference call as 
needed.  Telephone and email will be a primary means of daily communication between 
members of the Trial Management Group.  
1.2 Trial Steering Committee (TSC) 
 
The Trial Steering Committee will be composed of the trial investigators, members of the trial 
team at the Administrative and Data Coordinating Centres in addition to an independent 
chairperson and independent experts in the field of cleft palate surgery, speech therapy and 
biostatistics. 
 
The role of the Trial Steering Committee is to provide overall supervision for the trial and 
provide advice through its independent Chairman. The ultimate decision for the continuation 
of the trial lies with the Trial Steering Committee. The Trial Steering Committee will meet at 
least annually by teleconference.  Other meetings will be held by bimonthly teleconference call 
as needed.  E-mail will be a primary means of communication between members of the Trial 
Steering Committee. The Trial Steering Committee may also make recommendations to the 
Funder who may withdraw funding of the study.   
 
1.3 Data and Safety Monitoring Board (DSMB) 
 
The composition of the Data and Safety Monitoring Board will be decided by the National 
Institute of Health / National Institute of Dental and Craniofacial Research (NIH/NIDCR) and 
the initial committee meeting will be convened prior to the trial commencing.  
 
The Data and Safety Monitoring Board is an independent (should not be involved with the trial 
in any other way or have some competing interest that could impact on the trial) 
multidisciplinary group consisting of at least one statistician and at least one clinician that, 
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collectively, have experience in the management of children with cleft palate and in the conduct 
of randomised controlled trials. 
 
The Data and Safety Monitoring Board will be responsible for reviewing and assessing 
recruitment, interim monitoring of safety, trial conduct and external data. 
 
The full terms of reference and roles of the Data and Safety Monitoring Board are detailed in 
the Data and Safety Monitoring Board Charter and a copy of the open minutes from each 
DSMB meeting will be provided to the Program Official at National Institute of Dental and 
Craniofacial Research. 
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Supplementary Material No. 5:    
Ethics Approval and Summary of substantial protocol amendments 
Research Ethics Committees Approval 
In the UK, the TOPS Protocol version 1.1 and accompanying consent forms and their amendments 
have been approved by the Multicentre Research Ethics Committee in the UK (Yorkshire and the 
Humber – Leeds East) on 008 January 2010. 
In Brazil, approvals were gained from the Ethics in Research on Human Beings Commission 
(Comitê de Ética em Pesquisa em Seres Humanos) of the Hospital for Rehabilitation of 
Craniofacial Anomalies (Hospital de Reabilitação de Anomalias Craniofaciais Universidade da 
São Paulo, HRAC-USP), and from the National Ethics in Research Commission (Comissão 
Nacional de Ética em Pesquisa, CONEP from the Conselho Nacional de Saúde).  
In Denmark, approvals were received from the Institutional Review Board for the Central 
Denmark Region (De Videnskabsetiske Komiteer For Region Midtjylland). 
In Sweden, the ethics committee approving the TOPS Protocol was the Regional Ethical Review 
Board in Stockholm (Regionala Etikprövningsnämnden i Stockholm) 
In Norway, the regional committee for medical and health care research ethics in South-east 
Norway (Regional komité for medisinsk forskningsetikk sør-øst Norge, REK sør-øst B) gave 
ethical approval for the TOPS project.  Table 1 summarises the international approval for the 
TOPS protocol and subsequent amendments.  
Table 1: International approval of the TOPS protocol and subsequent amendments by the national 
and local Research Ethics Committees  
Protocol  Approval Dates  
Version 
No 
Version 
Date 
UK  Sweden Denmark Norway Brazil 
1.1 02/11/2009 08/01/2010         
2 10/03/2010 26/05/2010         
2.1 06/09/2010 28/09/2010 18/11/2010 04/07/2011 20/09/2011 11/03/2011, 
27/04/2011, 
10/05/2011
* 
3 01/05/2013 27/06/2013 11/02/2014 09/05/2014 18/12/2013 26/08/2014 
4 26/08/2015 01/10/2015 22/12/2015 09/11/2016 12/08/2016 06/11/2016 
5 22/08/2018 16/11/2018 03/01/2019 21/03/2019 TBC 30/04/2019 
 
* Local REC approval followed by the national REC approval in Brazil  
TBC: to be confirmed 
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TOPS Protocol Version 2.0 (10 Mar 2010)  
There were major amendments from version 1.0 to version 2.0, as summarised below. 
The secondary outcomes of the trial have been amended to include growth at age 12 months, which 
will be assessed by heel to crown length, nude weight and occipitofrontal circumference. 
In addition, total speech and language intervention together with total speech therapy will be 
assessed at age 3 and age 5 years. 
The wording of the postoperative complications outcome has been amended to 
“Postoperative/long term complications: infection, wound dehiscence and fistula”. 
The TOPS protocol has been amended to include a pilot speech study, which will allow the training 
of speech therapists, involved in the TOPS trial, in the collection of a speech sample. The 
amendment requests that sample speech recordings are made in children with a cleft palate. 
Between 1 and 5 recordings will be made for each of the three age groups: 10-12 months, 34-38 
months, 58-62 months. The number of recordings made will depend upon the experience of the 
speech therapists. A set of additional parent information sheets and consent forms have been 
included for parents and children who would like to participate in this pilot study. 
 
TOPS Protocol Version 3.0 (01 May 2013)  
There were major amendments to V3.0. Key changes are summarised below: 
The timing of adverse event reporting was clarified so that adverse events taking place in the 30 
day post-operative period only were reported. Unanticipated problems will continue to be reported 
throughout the full trial duration. 
Changes were made into the audiology assessments. After discussion with the OM8-30 
questionnaire, developer concerns were raised about the version control and validation of the 
questionnaire. The OM8-30 questionnaire for the assessment for glue ear will no longer be used.  
The inclusion/exclusion criteria was amended. Participants may now be included in the trial if they 
have Van Der Woude syndrome, as this syndrome is not considered to have an impact on 
development or speech and language. The exclusion criteria now states: 
Infants with syndromic cleft palate (except Van der Woude syndrome, which can be included if 
hearing is not affected) or severe developmental delay.  
 
Initially it was planned for teams to make follow up phone calls with participants at age 2 and 4 
years. However, patients are regularly seen in clinic and so this was no longer considered 
necessary.  
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To help reduce the burden to sites data entry will now be completed centrally at the Data 
Coordinating Centre and this has been clarified in the protocol.  
Other changes included amendments to the parent information sheets and consent forms (PISC) 
format to help ensure that the correct version (pilot study or main trial) was used.  The PISC was 
also amended to reflect the changes to assessments and follow up telephone calls and to include 
an optional item for parents to consent to be contacted by other researchers regarding related 
research.  
 
TOPS Protocol Version 4.0 (26 Aug 2015) The key changes introduced with major amendments 
from V3.0 to V4.0 were a very short questionnaire for the participants’ parents (ICS (Intelligibility 
in context scale) questionnaire) and a new supplementary Parent Information and Consent form to 
arrange for consent to collect information using the ICS questionnaire. Furthermore, changes were 
made to the Pilot Parent Information and Consent form and there were also modifications to the 
secondary outcome measures. Finally, changes were made to the section of the protocol covering 
indemnity. Please see a brief summary of the changes listed below:  
1. Intelligibility in context scale (ICS) questionnaire added to the speech assessments at 5 
years  
2. New supplementary Parent Information and Consent form, asking for consent to collect 
data using ICS and from local speech therapists  
3. Pilot Parent Information and Consent form was amended, it now also covers collection of 
data using ICS and nasometer at 5 years, and includes an additional consent clause #5, 
stating that recordings will be sent to the Data Coordinating Centre in Liverpool.  
4. Changes to secondary outcomes summarised:  
i. Change of secondary outcome “Velopharyngeal composite score summary at age 
3 years and 5 years”, to “Velopharyngeal composite score summary at 5 years”, as 
VPC-sum at 3 years is no longer possible (because this measure was recently found 
not to be reliable with 3year olds). 
ii. Addition of detail to definition of secondary outcome measures No. 38: the details 
added now show the components of the outcome measures; The provision of detail 
made it necessary to split the outcome measure “Articulation” into two outcome 
measures: “Articulation at age 3 years” and “Articulation at age 5 years”, as these 
are assessed in different ways; Also, the outcome measure “Audiological 
assessment (audiometry and tympanometry)” has now been split into “Hearing 
level” and “Middle ear function”. While this addition of detail results in an increase 
of the number of secondary outcome measures listed, the actual outcome measures 
No. 3-8 have not changed since the last version of the protocol;  
iii. Removal of the two secondary outcome measures “Total speech and language 
therapist intervention at age 3 and age 5 years” and “Total speech therapy sessions 
at age 3 and age 5 years” as these are recorded as background data, and do no longer 
constitute secondary outcome measures.  
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5. Section 14, Indemnity (page 77 in protocol): Section had initially described University of 
Manchester as a “cosponsor for international sites” – this has been corrected and clarified 
in detail: the University of Manchester is the sole Sponsor for the TOPS trial. For sites in 
the United Kingdom, the University of Manchester as Sponsor will provide Indemnity for 
the trial protocol. For all other trial sites, the University of Manchester will ensure that 
appropriate indemnity is in place at the trial site via the contractual agreements in place. 
The roles and responsibilities of the Administrative Centre, Data Coordinating Centre and 
the trial sites involved in the TOPS trial will be defined in a Division of Responsibilities 
document, which will form part of any signed contractual agreements. 
 
TOPS Protocol Version 5.0 (22 August 2018)  
The key change in this substantial amendment was introduction of additional outcome measures 
to enable the trial team to make the best use of the existing data collected.  The amendment 
included the addition of nasalance score to the TOPS Statistical Analysis Plan, as an exploratory 
analysis but not as a standalone outcome. This is to compare consistency between Speech and 
Language Therapist’s assessment of hypernasality and nasalance score. The additional outcome 
measures added to the protocol version 5.0 are summarised below along with the rational for the 
changes:  
 
1. VPC-rate was added because it is important to assess velopharyngeal function not only 
on single words but also on spontaneous speech at age 5, the most common 
communication condition; this is the same outcome measure as for the 3 year follow up 
assessment.  
 
2. Velopharyngeal insufficiency symptoms from single words will support the overall 
assessment of velopharyngeal function assessed from spontaneous speech at age 3.  
 
3. Assessment of oral consonant errors contributes to a better understanding of the speech 
errors made by children with Cleft Palate; this is the same outcome measure as for the 5 
year assessment. This change will make it possible to follow the prevalence 
longitudinally.  
 
The above changes to the outcome measures will not affect site activity nor require any 
additional data to be collected from patients or affect their safety.  
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SPIRIT Checklist- TOPS Protocol Paper V11.0  
Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised trial of 
palate surgery at 6 months versus 12 months of age  
Reporting checklist for protocol of a clinical trial 
. 
 
  Reporting Item Page Number 
Title #1 Descriptive title identifying the study design, 
population, interventions, and, if applicable, 
trial acronym 
1 
Trial registration #2a Trial identifier and registry name. If not yet 
registered, name of intended registry 
1 
Trial registration: 
data set 
#2b All items from the World Health Organization 
Trial Registration Data Set 
12  
Protocol version #3 Date and version identifier 1 & Supplementary 
files 
Funding #4 Sources and types of financial, material, and 
other support 
1 and 13 
Roles and 
responsibilities: 
contributorship 
#5a Names, affiliations, and roles of protocol 
contributors 
12-13 
Roles and 
responsibilities: 
sponsor contact 
information 
#5b Name and contact information for the trial 
sponsor 
13 
Roles and 
responsibilities: 
sponsor and funder 
#5c Role of study sponsor and funders, if any, in 
study design; collection, management, 
analysis, and interpretation of data; writing of 
the report; and the decision to submit the 
report for publication, including whether they 
13 and 
Supplementary 
material No 4 
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will have ultimate authority over any of these 
activities 
Roles and 
responsibilities: 
committees 
#5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, 
endpoint adjudication committee, data 
management team, and other individuals or 
groups overseeing the trial, if applicable (see 
Item 21a for data monitoring committee) 
11 and 
Supplementary 
material No 4 
Background and 
rationale 
#6a Description of research question and 
justification for undertaking the trial, including 
summary of relevant studies (published and 
unpublished) examining benefits and harms for 
each intervention 
1 and  2 
Background and 
rationale: choice of 
comparators 
#6b Explanation for choice of comparators 1 and 2 
Objectives #7 Specific objectives or hypotheses 2 
Trial design #8 Description of trial design including type of trial 
(eg, parallel group, crossover, factorial, single 
group), allocation ratio, and framework (eg, 
superiority, equivalence, non-inferiority, 
exploratory) 
3 
Study setting #9 Description of study settings (eg, community 
clinic, academic hospital) and list of countries 
where data will be collected. Reference to 
where list of study sites can be obtained 
3 
Eligibility criteria #10 Inclusion and exclusion criteria for participants. 
If applicable, eligibility criteria for study centres 
and individuals who will perform the 
interventions (eg, surgeons, psychotherapists) 
4 
Interventions: 
description 
#11a Interventions for each group with sufficient 
detail to allow replication, including how and 
when they will be administered 
5 
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Interventions: 
modifications 
#11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, 
drug dose change in response to harms, 
participant request, or improving / worsening 
disease) 
NA 
Interventions: 
adherance 
#11c Strategies to improve adherence to 
intervention protocols, and any procedures for 
monitoring adherence (eg, drug tablet return; 
laboratory tests) 
4, 7 and 8 
Interventions: 
concomitant care 
#11d Relevant concomitant care and interventions 
that are permitted or prohibited during the trial 
NA 
Outcomes #12 Primary, secondary, and other outcomes, 
including the specific measurement variable 
(eg, systolic blood pressure), analysis metric 
(eg, change from baseline, final value, time to 
event), method of aggregation (eg, median, 
proportion), and time point for each outcome. 
Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly 
recommended 
5-7 
Participant timeline #13 Time schedule of enrolment, interventions 
(including any run-ins and washouts), 
assessments, and visits for participants. A 
schematic diagram is highly recommended 
(see Figure) 
8-9 & Figure 1 
Sample size #14 Estimated number of participants needed to 
achieve study objectives and how it was 
determined, including clinical and statistical 
assumptions supporting any sample size 
calculations 
10 
Recruitment #15 Strategies for achieving adequate participant 
enrolment to reach target sample size 
3&10 
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Allocation: 
sequence 
generation 
#16a Method of generating the allocation sequence 
(eg, computer-generated random numbers), 
and list of any factors for stratification. To 
reduce predictability of a random sequence, 
details of any planned restriction (eg, blocking) 
should be provided in a separate document 
that is unavailable to those who enrol 
participants or assign interventions 
4  
Allocation 
concealment 
mechanism 
#16b Mechanism of implementing the allocation 
sequence (eg, central telephone; sequentially 
numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence 
until interventions are assigned 
NA 
Allocation: 
implementation 
#16c Who will generate the allocation sequence, 
who will enrol participants, and who will assign 
participants to interventions 
4-5 
Blinding (masking) #17a Who will be blinded after assignment to 
interventions (eg, trial participants, care 
providers, outcome assessors, data analysts), 
and how 
5 
Blinding (masking): 
emergency 
unblinding 
#17b If blinded, circumstances under which 
unblinding is permissible, and procedure for 
revealing a participant’s allocated intervention 
during the trial 
NA/ speech 
assessments  are 
carried out under 
blinded conditions 
Data collection 
plan 
#18a Plans for assessment and collection of 
outcome, baseline, and other trial data, 
including any related processes to promote 
data quality (eg, duplicate measurements, 
training of assessors) and a description of 
study instruments (eg, questionnaires, 
laboratory tests) along with their reliability and 
validity, if known. Reference to where data 
collection forms can be found, if not in the 
protocol 
9-10 
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Data collection 
plan: retention 
#18b Plans to promote participant retention and 
complete follow-up, including list of any 
outcome data to be collected for participants 
who discontinue or deviate from intervention 
protocols 
10 and Text box 1 
Data management #19 Plans for data entry, coding, security, and 
storage, including any related processes to 
promote data quality (eg, double data entry; 
range checks for data values). Reference to 
where details of data management procedures 
can be found, if not in the protocol 
10 
Statistics: 
outcomes 
#20a Statistical methods for analysing primary and 
secondary outcomes. Reference to where 
other details of the statistical analysis plan can 
be found, if not in the protocol 
11 
Statistics: 
additional analyses 
#20b Methods for any additional analyses (eg, 
subgroup and adjusted analyses) 
11 and 12 
Statistics: analysis 
population and 
missing data 
#20c Definition of analysis population relating to 
protocol non-adherence (eg, as randomised 
analysis), and any statistical methods to 
handle missing data (eg, multiple imputation) 
11 and 12 
Data monitoring: 
formal committee 
#21a Composition of data monitoring committee 
(DMC); summary of its role and reporting 
structure; statement of whether it is 
independent from the sponsor and competing 
interests; and reference to where further 
details about its charter can be found, if not in 
the protocol. Alternatively, an explanation of 
why a DMC is not needed 
12 and 
Supplementary 
material No 1 
Data monitoring: 
interim analysis 
#21b Description of any interim analyses and 
stopping guidelines, including who will have 
access to these interim results and make the 
final decision to terminate the trial 
12 and 
Supplementary 
Material No 1 
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Harms #22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously 
reported adverse events and other unintended 
effects of trial interventions or trial conduct 
8, 12 and 
Supplementary 
Material No 1 
Auditing #23 Frequency and procedures for auditing trial 
conduct, if any, and whether the process will 
be independent from investigators and the 
sponsor 
11 and 
Supplementary 
Material No 4 
Research ethics 
approval 
#24 Plans for seeking research ethics committee / 
institutional review board (REC / IRB) approval 
1, 1 and 
Supplementary 
Material No 5 
Protocol 
amendments 
#25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC / IRBs, trial participants, 
trial registries, journals, regulators) 
Supplementary 
Material No 5 
Consent or assent #26a Who will obtain informed consent or assent 
from potential trial participants or authorised 
surrogates, and how (see Item 32) 
4 and supplementary 
Materials No 1, 2 and 
3 
Consent or assent: 
ancillary studies 
#26b Additional consent provisions for collection and 
use of participant data and biological 
specimens in ancillary studies, if applicable 
Supplementary 
Materials 2 and 3  
Confidentiality #27 How personal information about potential and 
enrolled participants will be collected, shared, 
and maintained in order to protect 
confidentiality before, during, and after the trial 
12 &Supplementary 
Materials No 1 and 2 
Declaration of 
interests 
#28 Financial and other competing interests for 
principal investigators for the overall trial and 
each study site 
13 
Data access #29 Statement of who will have access to the final 
trial dataset, and disclosure of contractual 
agreements that limit such access for 
investigators 
12-13 
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Ancillary and post 
trial care 
#30 Provisions, if any, for ancillary and post-trial 
care, and for compensation to those who 
suffer harm from trial participation 
NA 
Dissemination 
policy: trial results 
#31a Plans for investigators and sponsor to 
communicate trial results to participants, 
healthcare professionals, the public, and other 
relevant groups (eg, via publication, reporting 
in results databases, or other data sharing 
arrangements), including any publication 
restrictions 
12  
Dissemination 
policy: authorship 
#31b Authorship eligibility guidelines and any 
intended use of professional writers 
12 
Dissemination 
policy: reproducible 
research 
#31c Plans, if any, for granting public access to the 
full protocol, participant-level dataset, and 
statistical code 
12 
Informed consent 
materials 
#32 Model consent form and other related 
documentation given to participants and 
authorised surrogates 
Supplementary 
Materials No 1, 2 and 
3 
Biological 
specimens 
#33 Plans for collection, laboratory evaluation, and 
storage of biological specimens for genetic or 
molecular analysis in the current trial and for 
future use in ancillary studies, if applicable 
4, 10 and 
Supplementary 
materials No 1 
The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
BY-ND 3.0. This checklist can be completed online using https://www.goodreports.org/, a tool made 
by the EQUATOR Network in collaboration with Penelope.ai 
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